HC Wainwright Predicts Cytosorbents FY2028 Earnings

Cytosorbents Co. (NASDAQ:CTSO) – Equities researchers at HC Wainwright issued their FY2028 earnings estimates for Cytosorbents in a research report issued to clients and investors on Thursday, April 3rd. HC Wainwright analyst S. Lee forecasts that the medical research company will earn ($0.07) per share for the year. HC Wainwright currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents’ FY2029 earnings at ($0.05) EPS.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.04. The firm had revenue of $9.20 million for the quarter, compared to analyst estimates of $10.09 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%.

Several other equities research analysts also recently commented on the company. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a report on Tuesday, April 1st. StockNews.com started coverage on Cytosorbents in a report on Thursday. They set a “hold” rating for the company. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Trading Down 2.0 %

CTSO opened at $0.97 on Friday. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.61. The company has a market cap of $53.04 million, a P/E ratio of -2.69 and a beta of 0.78. The company has a fifty day moving average price of $1.07 and a two-hundred day moving average price of $1.04. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Institutional Investors Weigh In On Cytosorbents

Several large investors have recently made changes to their positions in CTSO. Avenir Corp grew its position in shares of Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after acquiring an additional 118,387 shares during the period. Skylands Capital LLC increased its holdings in Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after acquiring an additional 26,195 shares during the period. Geode Capital Management LLC raised its position in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Cytosorbents in the 4th quarter valued at about $99,000. Finally, Northern Trust Corp lifted its position in Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 16,701 shares during the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.